News & Updates

Tetracyline vs clindamycin–rifampicin: which is more effective for hidradenitis suppurativa?

05 Aug 2021 by

Both tetracycline treatment and clindamycin–rifampicin combination therapy demonstrate significant efficacy after 12 weeks in patients with hidradenitis suppurativa (HS), reports a study. Regardless of disease severity, efficacy does not substantially differ between the two treatments.

Tetracyline vs clindamycin–rifampicin: which is more effective for hidradenitis suppurativa?

05 Aug 2021

Ixekizumab safe, effective up to 5 years in moderate-to-severe plaque psoriasis

03 Aug 2021 by

Treatment with ixekizumab (IXE) for moderate-to-severe plaque psoriasis is consistently safe and effective through 264 weeks in patients using the approved dose, according to the UNCOVER-3 study.

Ixekizumab safe, effective up to 5 years in moderate-to-severe plaque psoriasis

03 Aug 2021

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)

02 Aug 2021

New drug applications approved by US FDA as of 16-31 July 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)

02 Aug 2021

T-cell responses to BNT162b2 vaccine not weakened by methotrexate

26 Jul 2021 by

Patients with psoriasis taking the immunosuppressant methotrexate had low antibody responses to SARS-CoV-2 after receiving the first dose of Pfizer-BioNTech’s BNT162b2 vaccine but had shown T-cell responses, according to a study that was the first to look at T-cell responses in patients taking methotrexate.

T-cell responses to BNT162b2 vaccine not weakened by methotrexate

26 Jul 2021

Bimekizumab triumphs over secukinumab in improving skin clearance in plaque psoriasis

13 Jul 2021 by

Bimekizumab appeared to be more effective than secukinumab in improving skin clearance in patients with moderate-to-severe plaque psoriasis, according to the multinational, phase IIIb BE RADIANT trial presented at AAD 2021.

Bimekizumab triumphs over secukinumab in improving skin clearance in plaque psoriasis

13 Jul 2021

$Tirabrutinib impresses in refractory pemphigus trial$

Tirabrutinib impresses in refractory pemphigus trial

13 Jul 2021

Use of the highly selective oral Bruton’s tyrosine kinase inhibitor tirabrutinib appears effective in the treatment of patients with refractory pemphigus, inducing remission and cutting oral corticosteroid use without major safety concerns, according to data from a phase II trial.

Tirabrutinib impresses in refractory pemphigus trial

13 Jul 2021

Time from melanoma excision to sentinel node biopsy does not affect outcomes

12 Jul 2021

A short interval as compared to a long one between the primary melanoma excision and obtaining a sentinel lymph node biopsy specimen demonstrate similar patient outcomes, reports a recent study.

Time from melanoma excision to sentinel node biopsy does not affect outcomes

12 Jul 2021

Which medication is most effective for nail psoriasis?

10 Jul 2021

A systematic review and network meta-analysis of studies assessing small molecule inhibitors and biologic drugs show that tofacitinib and ixekizumab are the most effective treatments for nail psoriasis in 10 to 16 weeks and 24 to 26 weeks, respectively.

Which medication is most effective for nail psoriasis?

10 Jul 2021

Low-dose skin electron beam therapy improves skin QOL in mycosis fungoides

10 Jul 2021

Low-dose skin electron beam therapy using a rotational technique demonstrates a very high overall response rate and an improvement in skin-related quality of life (QOL) in patients with mycosis fungoides, the most common form of cutaneous T-cell lymphoma, reports a recent study.

Low-dose skin electron beam therapy improves skin QOL in mycosis fungoides

10 Jul 2021

Topical terbinafine effective against mild-to-moderate onychomycosis

09 Jul 2021

Topical terbinafine 10% solution (MOB-015) is a viable option for the treatment of mild-to-moderate distal subungual onychomycosis, with an adverse event profile similar to vehicle, suggests a study.

Topical terbinafine effective against mild-to-moderate onychomycosis

09 Jul 2021

News & Updates

Filter by Specialty:

Specialty:

Tetracyline vs clindamycin–rifampicin: which is more effective for hidradenitis suppurativa?

Tetracyline vs clindamycin–rifampicin: which is more effective for hidradenitis suppurativa?

Ixekizumab safe, effective up to 5 years in moderate-to-severe plaque psoriasis

Ixekizumab safe, effective up to 5 years in moderate-to-severe plaque psoriasis

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)

T-cell responses to BNT162b2 vaccine not weakened by methotrexate

T-cell responses to BNT162b2 vaccine not weakened by methotrexate

Bimekizumab triumphs over secukinumab in improving skin clearance in plaque psoriasis

Bimekizumab triumphs over secukinumab in improving skin clearance in plaque psoriasis

Tirabrutinib impresses in refractory pemphigus trial

Tirabrutinib impresses in refractory pemphigus trial

Time from melanoma excision to sentinel node biopsy does not affect outcomes

Time from melanoma excision to sentinel node biopsy does not affect outcomes

Which medication is most effective for nail psoriasis?

Which medication is most effective for nail psoriasis?

Low-dose skin electron beam therapy improves skin QOL in mycosis fungoides

Low-dose skin electron beam therapy improves skin QOL in mycosis fungoides

Topical terbinafine effective against mild-to-moderate onychomycosis

Topical terbinafine effective against mild-to-moderate onychomycosis